March 25, 2026
As President Trump sees the possibility of diplomacy as his comments signal a possible Iran de-escalation. Yesterday all 3 major averages posted losses, “uncle algo and his electronic trading dwarfs” are thirsting after the oversold
As I wrote in Monday’s closing bell, “Digging through the ruble of share pricing on Tuesday. … I am STILL a wait and HOLD!”
Pre-open Signals: 7 Positive indications
News: Beam Therapeutics (BEAM +$2.25 or +9.39% to $26.20 pre-open) updated safety and efficacy data from the ongoing P1/2 trial of BEAM-302 and the selection of 60 mg as the optimal biological dose to advance into pivotal development to support potential accelerated approval. BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation designed to directly correct the underlying genetic mutation that causes the severe form of alpha-1 antitrypsin deficiency (AATD) through base editing. AATD is a serious genetic disease that can lead to significant liver disease.
Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!
March 19, 2026
3/19 - Harvard Apparatus RT (OTCQB: HRGN dived -0.28 or -16.67% to $1.40 on 1 share traded
... after Wednesday’s $0.00 after Tuesday’s a.m., drop -$0.37 and closing down -$0.04 with 4,985 shares traded after barely trading lately)
Reinforces Ponzi Scheme!
Financing ... (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity”
Such a deal, next joke!
Broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands to partners and employees past and present; even was sued and had to pay for a patient DEATH, usually a death knell foe any company!
WHO and WHAT is its owner ... a Beijing, China percentage (%) “owned”, financed and run company … with patterns of share pricing manipulation? Cash starved, NO clinical data after 5-year ago IND
March 24, 2026
Duped over relief, conflagration (no war declared), oil, Ai and software jitters
My view, stay in a line of sight
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision
Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!
March 19, 2026
3/19 - Harvard Apparatus RT (OTCQB: HRGN dived -0.28 or -16.67% to $1.40 on 1 share traded ... after Wednesday’s $0.00 after Tuesday’s a.m., drop -$0.37 and closing down -$0.04 with 4,985 shares traded after barely trading lately) Reinforces Ponzi Scheme! Financing ... (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity” Entered into Securities Purchase Agreements with Investors agreeing to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $700 K and a purchase price per share of $1.70. A cheap date; WHY hasn’t Beijing, China stepped-up???? While ... broke and seriously in debt to partners, how long will these $$ last? Such a deal, next joke! Broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands to partners and employees past and present; even was sued and had to pay for a patient DEATH, usually a death knell foe any company! Guess who's providing the lipstick for this pig! WHO and WHAT is its owner ... a Beijing, China percentage (%) “owned”, financed and run company … with patterns of share pricing manipulation? Cash starved, NO clinical data after 5-year ago IND Accumulated deficit to date = $103.2 M in 12 years ... U.S. investors BEWARE, forewarned is forearmed?
March 8, 2026
14.9 M shares priced at $5.61 with a positive +$0.15 or +2.22% Monday pre-open Oversubscribed, 3/6/26 The private placement was anchored by existing and new investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others.
February 15, 2026
A scorecard of covered companies Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status" I have written what I as an investor would want to know … Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
6 hours 39 min ago
RMi Pre-opening; Waiting for a tailwind
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
